Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06207123 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
A Phase 1 study of Acute Leukemia and Lymphoblastic Lymphoma, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT06207123: Recruiting Phase 1 study of Acute Leukemia and Lymphoblastic Lymphoma, sponsored by University of Chicago.
NCT06207123 is a Phase 1 study of Acute Leukemia and Lymphoblastic Lymphoma that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 15 participants, below the 463-participant average among 37 other Acute Leukemia trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06207123, a Phase 1 study of Acute Leukemia and Lymphoblastic Lymphoma, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphoblastic leukemia.
Primary Outcome
Recommended phase II dose for combination of LP-118, ponatinib, vincristine and dexamethasone as assessed by rate of dose-limiting toxicities among study participants.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Methotrexate
- DRUG Ponatinib
- DRUG LP-118
Study Locations (2)
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
New York
- University of Rochester Medical Center, Wilmot Cancer Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-09-13 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
What NCT06207123 shows while recruiting
NCT06207123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 463-participant average among 37 other Acute Leukemia trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Acute Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT06207123 reports a single indexed study location in Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT06207123 about?
NCT06207123 is a clinical study titled "A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)". The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphobl...
What is the current status of trial NCT06207123?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-09-13. Estimated completion is 2026-12-01.
What conditions does trial NCT06207123 study?
This clinical trial studies the following conditions: Acute Leukemia, Lymphoblastic Lymphoma, Lymphoblastic Leukemia.
What interventions are being tested in trial NCT06207123?
The interventions under investigation include: Dexamethasone (DRUG), Vincristine (DRUG), Methotrexate (DRUG), Ponatinib (DRUG), LP-118 (DRUG).
Who is sponsoring clinical trial NCT06207123?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06207123 being conducted?
This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06207123's enrollment target sits among peer trials
15 35th of 37 higher than 3 of 37 other Acute Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
RECRUITING · Phase 1
-
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
RECRUITING · Phase 1
-
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
RECRUITING · Phase 1
-
A Study of Revumenib and Mezigdomide in People With Leukemia
RECRUITING · Phase 1
-
TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT
ACTIVE NOT RECRUITING · Phase 1
-
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI